{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:43:48Z","timestamp":1790023428668,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102571","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T22:19:36Z","timestamp":1777846776000},"page":"102571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer Outside of Randomized Controlled Trials: A Systematic Review and Meta-Analysis of Prognostic Factors in Real-World Analyses"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-669X","authenticated-orcid":false,"given":"Keiichiro","family":"Miyajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Chlosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clgc.2026.102571_bib0001","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102571_bib0002","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.clgc.2026.102571_bib0003","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"10336","key":"10.1016\/j.clgc.2026.102571_bib0004","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clgc.2026.102571_bib0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102571_bib0006","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102571_bib0007","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102571_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.1209","article-title":"PSMAddition: phase 3 trial of [177lu]Lu-PSMA-617 plus standard of care (SoC) vs. Soc alone in patients with metastatic hormone-sensitive prostate cancer","volume":"120","author":"Kim","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"10.1016\/j.clgc.2026.102571_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413519","article-title":"An insight on novel molecular pathways in metastatic prostate cancer: a focus on DDR, MSI and AKT","volume":"22","author":"Mollica","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clgc.2026.102571_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030546","article-title":"Bone targeting agents in patients with metastatic prostate cancer: state of the art","volume":"13","author":"Mollica","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.clgc.2026.102571_bib0011","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17425255.2021.1970745","article-title":"Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis","volume":"17","author":"Rizzo","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clgc.2026.102571_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2026.102571_bib0013","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.clgc.2026.102571_bib0014","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.euo.2024.04.004","article-title":"The State of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024","volume":"7","author":"Miszczyk","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102571_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eururo.2024.10.017","article-title":"What's in a name? Why words matter in advanced prostate cancer","volume":"87","author":"Oh","year":"2025","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102571_bib0016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2026.102571_bib0017","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.euros.2024.10.008","article-title":"Prognostic expression signature of RB1, PTEN, and TP53 genes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor pathway inhibitors","volume":"70","author":"de Herreros","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.clgc.2026.102571_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102191","article-title":"Real-world efficacy and safety of low-dose abiraterone with food and standard-dose abiraterone in de novo metastatic hormone-sensitive prostate cancer: a retrospective analysis","volume":"22","author":"Do","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"14","key":"10.1016\/j.clgc.2026.102571_bib0019","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/pros.70017","article-title":"Prognostic impact of initial prostate-specific antigen in metastatic hormone-sensitive prostate cancer patients with extensive bone metastases under androgen receptor signaling inhibitor","volume":"85","author":"Fujimoto","year":"2025","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.clgc.2026.102571_bib0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/pros.24876","article-title":"Prognostic nutritional index as a biomarker in metastatic hormone-sensitive prostate cancer: impact on survival and treatment optimization","volume":"85","author":"Hacioglu","year":"2025","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.clgc.2026.102571_bib0021","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/pros.24802","article-title":"Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy","volume":"85","author":"Narita","year":"2025","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.clgc.2026.102571_bib0022","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/pros.24865","article-title":"Immunohistochemical analysis of androgen receptor expression predicts the prognosis of metastatic castration-sensitive prostate cancer patients receiving abiraterone acetate","volume":"85","author":"Nishimoto","year":"2025","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.clgc.2026.102571_bib0023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/s12885-021-08206-8","article-title":"Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study","volume":"21","author":"Okamoto","year":"2021","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2026.102571_bib0024","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pros.24869","article-title":"The prognostic value of the prostate adenocarcinoma with ductal feature in patients with advanced prostate cancer treated with abiraterone acetate","volume":"85","author":"Shi","year":"2025","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.clgc.2026.102571_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102140","article-title":"Clinical outcomes and risk stratification in patients with metastatic hormone-sensitive prostate cancer treated with new-generation androgen receptor signaling inhibitors","volume":"22","author":"Suzuki","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102571_bib0026","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/iju.14754","article-title":"Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate","volume":"29","author":"Takahara","year":"2022","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102571_bib0027","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10147-024-02649-2","article-title":"Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium","volume":"30","author":"Uchimoto","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102571_bib0028","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/pros.24855","article-title":"Screening for predictive factors of efficacy of second-generation androgen receptor axis-targeted agents in patients with high-risk metastatic hormone-sensitive prostate cancer","volume":"85","author":"Ueda","year":"2025","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.clgc.2026.102571_bib0029","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pros.24809","article-title":"Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patients","volume":"85","author":"Wei","year":"2025","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.clgc.2026.102571_bib0030","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/pros.24710","article-title":"Predicting abiraterone efficacy in advanced prostate cancer: insights from marker of proliferation Ki67","volume":"84","author":"Zhao","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2026.102571_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-025-01067-3","article-title":"Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study","author":"B\u00fcttner","year":"2026","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.clgc.2026.102571_bib0032","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.euo.2024.11.005","article-title":"Apalutamide in metastatic castration-sensitive prostate cancer: results from the multicenter real-world ARON-3 study","volume":"8","author":"Santoni","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102571_bib0033","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.21873\/anticanres.15183","article-title":"Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer","volume":"41","author":"Blas","year":"2021","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.clgc.2026.102571_bib0034","first-page":"3877","article-title":"Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis","volume":"10","author":"Dai","year":"2018","journal-title":"Am J Transl Res"},{"issue":"10","key":"10.1016\/j.clgc.2026.102571_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102514","article-title":"Pre-treatment hemoglobin concentration and absolute monocyte count as independent prognostic factors for survival in localized or locally advanced prostate cancer patients undergoing radiotherapy","volume":"10","author":"Magrowski","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.clgc.2026.102571_bib0036","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.clgc.2019.07.009","article-title":"Prognostic value of lactate dehydrogenase in metastatic prostate cancer: a systematic review and meta-analysis","volume":"17","author":"Mori","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102571_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020205","article-title":"An updated systematic review and network meta-analysis of first-line triplet vs. doublet therapies for metastatic hormone-sensitive prostate cancer","volume":"17","author":"Matsukawa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2026.102571_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1599292","article-title":"Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach","volume":"19","author":"Zapatero","year":"2025","journal-title":"Oncol Rev"},{"issue":"5","key":"10.1016\/j.clgc.2026.102571_bib0039","doi-asserted-by":"crossref","first-page":"336.e1","DOI":"10.1016\/j.urolonc.2025.02.007","article-title":"Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: real-world data from a multicenter study","volume":"43","author":"Urabe","year":"2025","journal-title":"Urol Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102571_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309941","article-title":"Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients","volume":"19","author":"Lai","year":"2024","journal-title":"PLoS One"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:53:05Z","timestamp":1783943585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000716"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102571","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer Outside of Randomized Controlled Trials: A Systematic Review and Meta-Analysis of Prognostic Factors in Real-World Analyses","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102571"}}